Flt3 ligand delivered in a pluronic formulation prolongs the survival of mice with orthotopic pancreatic adenocarcinoma.

@article{Ashour2007Flt3LD,
  title={Flt3 ligand delivered in a pluronic formulation prolongs the survival of mice with orthotopic pancreatic adenocarcinoma.},
  author={Abdelkader Elbadawy Ashour and Hēth R Turnquist and Nicole M Burns and Xiaojian Wang and Xuede Lin and Jarrod R. Tremayne and Michael Anthony Hollingsworth and Joan M Blonder and Gary J. Rosenthal and James E Talmadge and Joyce C. Solheim},
  journal={Cancer biotherapy & radiopharmaceuticals},
  year={2007},
  volume={22 2},
  pages={235-8}
}
Pancreatic adenocarcinoma is a devastating disease, characterized by asymptomatic development and extremely poor prognosis. Given the resistance of pancreatic cancer to standard chemo- and radiotherapy, we have focused on the development of immunotherapies for this disease. The number of dendritic cells (DCs), natural killer (NK) cells, and T-cells in the blood and secondary lymphoid organs is regulated by a group of hematopoietic growth factors, which includes fms-like tyrosine kinase-3 ligand… CONTINUE READING